Published date: Sep 03 2024

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 22, Issue No. 7

Pages: 567– 578

DOI: 10.18502/ijrm.v22i7.16970

Tahereh Poordast

Saeed Alborzi

Ziba Kiani

Navid Omidifar

Elham Askary - elliaskary_md@yahoo.com

Kefayat Chamanara

Mansoureh Shokripour

Alimohammad Keshtvarz Hesam Abadi

Background: The lack of improvement in some endometriotic people’s pain after surgery even while using hormone treatment may suggest an inappropriate response to routine hormonal therapies.

Objective: This study aimed to determine a cut-off point for selecting the most appropriate treatment based on the hormone receptors of endometriotic lesions.

Materials and Methods: In this cross-sectional study, by reviewing the medical records of participants and testing their archive samples and phone interviews (if needed), 86 symptomatic women after endometriosis surgery who were operated into governmental hospitals, Shahid Faghihi and Hazrate Zeinab Shiraz Iran were enrolled between March 2017 and March 2019. Women were divided into 2 groups: responsiveness (n = 73 for dysmenorrhea, n = 60 for dyspareunia) to medical treatment and surgery, and unresponsiveness (n = 13, n = 7). We examined the pathological slides of 86 women to determine the amount of hormone receptors and the relationship between the type of medical treatment and the level of hormone receptors on pain relief within 1 yr after surgery.

Results: Based on the receiver operating characteristic curve, dysmenorrhea in the presence of tissue estrogen receptors > 60% (p = 0.1065), and dyspareunia in the presence of tissue progesterone receptors > 80% (p = 0.0001) responded well to medical treatment after surgery. In the presence of endometrioma-dysmenorrhea showed the best response to oral contraceptive pills (69.4%), while in deep infiltrative endometriosis-dyspareunia showed the best response to progesterone treatment (75%).

Conclusion: Prescribing an appropriate hormone therapy based on a specific immunohistochemistry staining pattern can improve the life quality of postoperative endometriosis individuals.

Key words: Endometriosis, Estrogen receptor, Progesterone receptor, Recurrence.

[1] Olive DL, Schwartz LB. Endometriosis. N Engl J Med 1993; 328: 1759–1769.

[2] Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012; 98: 511–519.

[3] Rossini R, Lisi G, Pesci A, Ceccaroni M, Zamboni G, Gentile I, et al. Depth of intestinal wall infiltration and clinical presentation of deep infiltrating endometriosis: Evaluation of 553 consecutive cases. J Laparoendosc Adv Surg Tech A 2018; 28: 152–156.

[4] Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: Endometriosis. Hum Reprod Open 2022; 2022: hoac009.

[5] Greene AD, Lang SA, Kendziorski JA, Sroga-Rios JM, Herzog TJ, Burns KA. Endometriosis: Where are we and where are we going? Reproduction 2016; 152: R63-R78.

[6] Bergqvist A, Fernö M. Estrogen and progesterone receptors in endometriotic tissue and endometrium: Comparison according to localization and recurrence. Fertil Steril 1993; 60: 63–68.

[7] García-Gómez E, Vázquez-Martínez ER, Reyes-Mayoral C, Cruz-Orozco OP, Camacho-Arroyo I, Cerbón M. Regulation of inflammation pathways and inflammasome by sex steroid hormones in endometriosis. Front Endocrinol 2020; 10: 935.

[8] Patel BG, Rudnicki M, Yu J, Shu Y, Taylor RN. Progesterone resistance in endometriosis: Origins, consequences and interventions. Acta Obstet Gynecol Scand 2017; 96: 623– 632.

[9] Ng S-W, Norwitz GA, Pavlicev M, Tilburgs T, Simón C, Norwitz ER. Endometrial decidualization: The primary driver of pregnancy health. Int J Mol Sci 2020; 21: 4092.

[10] Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 2000; 85: 2897– 2902.

[11] Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, et al. Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Mol Cell Endocrinol 2006; 248: 94–103.

[12] Cakmak H, Taylor HS. Molecular mechanisms of treatment resistance in endometriosis: The role of progesterone-hox gene interactions. Semin Reprod Med 2010; 28: 69–74.

[13] Reis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C, Petraglia F. Progesterone receptor ligands for the treatment of endometriosis: The mechanisms behind therapeutic success and failure. Hum Reprod Update 2020; 26: 565–585.

[14] Bulun SE, Cheng YH, Pavone ME, Xue Q, Attar E, Trukhacheva E, et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med 2010; 28: 36–43.

[15] Flores VA, Vanhie A, Dang T, Taylor HS. Progesterone receptor status predicts response to progestin therapy in endometriosis. J Clin Endocrinol Metab 2018; 103: 4561– 4568.

[16] Somigliana E, Vercellini P, Vigano P, Benaglia L, Busnelli A, Fedele L. Postoperative medical therapy after surgical treatment of endometriosis: From adjuvant therapy to tertiary prevention. J Minim Invasive Gynecol 2014; 21: 328–334.

[17] van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, et al. A scoring system for immunohistochemical staining: Consensus report of the task force for basic research of the EORTC-GCCG. J Clin Pathol 1997; 50: 801–804.

[18] Alborzi S, Rasekhi A, Shomali Z, Madadi G, Alborzi M, Kazemi M, et al. Diagnostic accuracy of magnetic resonance imaging, transvaginal, and transrectal ultrasonography in deep infiltrating endometriosis. Medicine 2018; 97: e9536.

[19] Nagini S. Breast cancer: Current molecular therapeutic targets and new players. Anticancer Agents Med Chem 2017; 17: 152–163.

[20] Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: A randomized controlled trial. Fertil Steril 2010; 94: 464–471.

[21] Miró AM, Sastre-Serra J, Pons DG, Valle A, Roca P, Oliver J. 17??-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol 2011; 123: 133–139.

[22] Munro MG. Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity. Fertil Steril 2019; 111: 629– 640.

[23] Torrisi R, Marrazzo E, Agostinetto E, De Sanctis R, Losurdo A, Masci G, et al. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what? Crit Rev Oncol Hematol 2021; 160: 103280.

[24] Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: A systematic review and meta-analysis. JAMA Oncol 2016; 2: 1477– 1486.

[25] Bruner-Tran KL, Herington JL, Duleba AJ, Taylor HS, Osteen KG. Medical management of endometriosis: Emerging evidence linking inflammation to disease pathophysiology. Minerva Ginecol 2013; 65: 199–213.

[26] Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol 2012; 138: 796–802.

[27] Garcia-Alonso L, Handfield L-F, Roberts K, Nikolakopoulou K, Fernando RC, Gardner L, et al. Mapping the temporal and spatial dynamics of the human endometrium in vivo and in vitro. Nat Genet 2021; 53: 1698–1711.

[28] Vassilopoulou L, Matalliotakis M, Zervou MI, Matalliotaki C, Spandidos DA, Matalliotakis I, et al. Endometriosis and in vitro fertilisation. Exp Ther Med 2018; 16: 1043–1051.

[29] Hou Zh, Mamillapalli R, Taylor HS. Predictive biomarkers may allow precision therapy of endometriosis. J Endometr Pelvic Pain Disord 2017; 9: 279–285.

[30] Nothnick WB. MicroRNAs and progesterone receptor signaling in endometriosis pathophysiology. Cells 2022; 11: 1096.

[31] Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 2007; 148: 3814–3826.

[32] Colón-Caraballo M, García M, Mendoza A, Flores I. Human endometriosis tissue microarray reveals sitespecific expression of estrogen receptors, progesterone receptor, and Ki67. Appl Immunohistochem Mol Morphol 2019; 27: 491–500.

[33] Tang Z-R, Zhang R, Lian Z-X, Deng S-L, Yu K. Estrogenreceptor expression and function in female reproductive disease. Cells 2019; 8: 1123.

[34] Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, et al. The expression ratios of estrogen receptor ?? (ER??) to estrogen receptor ??1 (ER??1) and ER?? to ER??2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol 2013; 44: 1047–1054.

[35] Chantalat E, Valera MC, Vaysse C, Noirrit E, Rusidze M, Weyl A, et al. Estrogen receptors and endometriosis. Int J Mol Sci 2020; 21: 2815.

[36] Peng H, Weng L, Lei S, Hou S, Yang S, Li M, et al. Hypoxiahindered methylation of PTGIS in endometrial stromal cells accelerates endometriosis progression by inducing CD16- NK-cell differentiation. Exp Mol Med 2022; 54: 890–905.

[37] Shao R, Cao S, Wang X, Feng Y, Billig H. The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. Am J Transl Res 2014; 6: 104–113.